Merck's MET inhibitor Tepmetko is approved by the UK MHRA for the treatment of NSCLC patients

CompilationFan Dongdong

A few days ago, the British Medicines and Healthcare Products Regulatory Agency (MHRA) announced the conditional approval of Merck's MET inhibitor Teppetko (tepotinib) for the treatment of certain non-small cell lung cancer (NSCLC) patients

The MHRA's decision to approve Teppetko was mainly based on the results of the Phase II VISION study, which evaluated Teppetko alone to treat patients with advanced or metastatic NSCLC with skip changes in METex14

Tepmetko is an oral MET kinase inhibitor developed internally by Merck.

In July this year, the British MHRA issued positive scientific opinions on Merck’s targeted anticancer drug Teppetko for the treatment of advanced non-small cell lung cancer (NSCLC) patients with skipping changes in exon 14 of the MET gene

It is worth noting that the authorization of Teppetko was carried out through the ORBIS project, which is a way coordinated by the U.

In March 2020, the drug was approved by the Japanese Ministry of Health, Labour and Welfare (MHLW), making Teppetko the world's first oral MET inhibitor approved for the treatment of advanced NSCLC patients with MET genetic changes

Reference source:

MHRA backs Merck's MET inhibitor Tepmetko